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A total of 53 women with chemotherapy-naı ¨ve stage Ic-IV ovarian cancer were treated with four cycles of carboplatin area under the
curve 7 every 3 weeks, followed by four cycles of paclitaxel 70mgm
 2 (days 1, 8, and 15) and gemcitabine 1000mgm
 2 (days 1 and
8) every 3 weeks. In all, 37 (70%) had stage III/IV disease, with 22 (42%) having tumour 42cm; 38 patients (72%) completed all
planned treatment; 27 of the 32 (84%) patients with radiologically evaluable disease had partial or complete responses; and 30 of the
39 patients (77%) with elevated cancer antigen (CA) 125 had a greater than 75% fall in this value. At a median follow-up of 28
months, 31 patients had relapsed with a median progression-free survival of 19.5 months. In total, 79% of patients were alive at 2
years. Common Toxicity Criteria grade 3/4 haematological toxicity, predominantly neutropenia, was seen in 57% of the patients. A
certain degree of pulmonary toxicity was observed; eight patients had symptomatic breathlessness, 7 decreased diffusing capacity of
the lung for carbon monoxide, and interstitial chest X-ray changes during the weekly phase. In all cases, this toxicity was reversible.
No significant neurotoxicity was seen. This regimen is generally well tolerated with encouraging efficacy. However, the observation of
pulmonary toxicity, potentially a feature of the weekly taxane–gemcitabine regimen, was of some concern. Alternative schedules,
including 3-weekly taxanes, are currently being evaluated.
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The majority of patients with epithelial ovarian cancer will require
chemotherapy. It is now well established that first-line treatment
should include a platinum compound (Harries and Gore, 2002),
with carboplatin being the drug of choice, having been shown to
have equivalent efficacy but less toxicity than cisplatin (Alberts,
1995; Du Bois et al, 1999; Ozols et al, 2003). Two large randomised
studies in the 1990s of first-line therapy for ovarian cancer showed
a survival benefit when a paclitaxel–platinum combination was
compared with the previous standard of cyclophosphamide–
cisplatin; therefore, the combination of platinum and paclitaxel
became standard first-line therapy (McGuire et al, 1996; Piccart
et al, 2000). Two other large randomised trials conducted
by the International Collaborative Ovarian Neoplasm (ICON)
group (ICON group, 2002) and the Gynaecologic Oncology Group
(GOG) (Muggia et al, 2000) failed to confirm the benefit of the
addition of paclitaxel to platinum. The reasons are unclear,
but a negative interaction between the two drugs is not excluded.
It is interesting to note that taxanes, when given in short infusions,
clearly reduce the thrombocytopenia expected from carboplatin;
again the mechanism is not understood. A number of patients
in the non-taxane-containing arms of the ICON and GOG
trials crossed over to receive paclitaxel at disease progression,
and since results were equivalent this suggests that there
may be no disadvantage to giving platinum and taxanes
sequentially rather than concurrently. The ICON group has
recently shown a benefit when paclitaxel was added to platinum
in patients with potentially platinum-sensitive relapsed disease
(Parmar et al, 2003).
Despite the benefits observed in the above trials, however, the
majority of women in these studies eventually died from their
disease, thus underscoring the importance of designing trials to
improve the results achieved with the combination of paclitaxel
and platinum. One approach is to add other potentially non-cross-
resistant agents and drugs that are being evaluated in this setting
include topotecan, liposomal doxorubicin, and gemcitabine.
Gemcitabine, a pyrimidine analogue, is active in untreated and
pretreated ovarian cancer. In a small study of chemonaive patients,
single-agent gemcitabine produced a modest overall response rate
of 18% (D’Agostino et al, 2003). In patients with platinum-
pretreated, relapsed ovarian cancer, response rates ranged from 13
to 28%, which are comparable with those of other agents (e.g.,
topotecan, liposomal doxorubicin, and paclitaxel) in a similar
patient population (Lund et al, 1994; Shapiro et al, 1996;
Friedlander et al, 1998; Silver and Piver, 1999; von Minckwitz
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let al, 1999; Underhill et al, 2001). Gemcitabine is generally well
tolerated with common toxicities including myelosuppression,
lethargy, flu-like symptoms, peripheral oedema, and skin rashes.
An unexplained rare severe pulmonary toxicity has been reported,
particularly in patients with lung cancer who have received prior
mediastinal radiotherapy (Sauer-Heilborn et al, 1999).
Gemcitabine in combination with platinum and paclitaxel as a
triplet regimen has been explored recently as first-line therapy for
ovarian cancer (Hansen et al, 1999; Hansen, 2002). Although the
response rate was highly favourable (overall response rate of 100%
in 25 evaluable patients), haematological toxicity was significant,
with grade 4 myelosuppression reported in 96% of patients.
In the trial reported here, we evaluated the addition of
gemcitabine to carboplatin and paclitaxel in a sequential regimen,
with carboplatin monotherapy followed by gemcitabine and
paclitaxel to chemonaive patients with ovarian cancer. A sequential
regimen in which carboplatin is given first and separately from
paclitaxel may reduce toxicity as well as decrease the possibility of
any antagonism between these agents. It might also take advantage
of the laboratory observation that the presence of p53 mutant cells
determines the relative efficacy of carboplatin and paclitaxel;
sequential treatment could theoretically be more effective through
activity on two subpopulations of tumour cells, one after the other
(Cassinelli et al, 2001). The feasibility of the regimen (i.e., the
ability to deliver the planned doses and its toxicity) and its efficacy
(response rates, cancer antigen (CA) 125 response rates, and
progression-free survival) are reported here.
PATIENTS AND METHODS
Eligibility criteria
Women aged 18 or older with chemotherapy-naı ¨ve histologically
confirmed epithelial ovarian, primary peritoneal, or fallopian tube
carcinomas were eligible for study entry. Patients had International
Federation of Gynaecology and Obstetrics (FIGO) stages Ic-IV
disease with or without successful cytoreductive surgery. Patients
with Ic disease were limited to those with malignant cells in ascitic
fluid, peritoneal washings or with tumour on the surface of the
ovary. Patients had to be within 8 weeks of initial laparotomy/
surgery and able to comply with follow-up requirements. Each
patient had to have an Eastern Cooperative Oncology Group
(ECOG) performance status of 0, 1, or 2. Adequate liver (bilirubin
pupper limit of normal (ULN), aspartate aminotransferase (AST)/
alanine aminotransferase (ALT) p1.5  ULN, or alkaline phos-
phatase (ALP) p3  ULN), renal (creatinine p1.25  ULN), and
bone marrow functions (neutrophils X1.5 10
9l
 1, platelets
X100 10
9l
 1, and haemoglobin X9.0gl
 1) were required.
Patients were excluded from the study if they had borderline
ovarian malignancies, ruptured capsule as the only evidence of
stage Ic, mixed mesodermal tumours, a previous malignancy
(except for in situ cervical cancer or non-melanoma skin cancer),
concurrent severe and/or uncontrolled co-morbid medical condi-
tions, history of prior serious allergic reactions (ie anaphylaxis), or
symptomatic peripheral neuropathy Xgrade 2 (National Cancer
Institute of Canada-Common Toxicity Criteria (CTC)). Other
exclusion criteria included: history of insulin-dependent diabetes
mellitus or other relative contraindications to corticosteroids or
pregnant or lactating women (or potentially fertile women not
using adequate contraception). The study was approved by the
local ethics committees, and written informed consent was
obtained from all patients before study entry.
Treatment plan
The chemotherapy regimen consisted of a total of eight cycles, with
four cycles of carboplatin area under the curve (AUC) 7
(glomerular filtration rate (GFR) calculated using
51Cr EDTA
clearance) given at 3-week intervals, followed by four cycles of
paclitaxel 70mgm
 2 on days 1, 8, and 15 and gemcitabine
1000mgm
 2 on days 1 and 8 at 3-week intervals. Carboplatin was
given as a 1-h infusion in 500ml 5% glucose. After completing
carboplatin therapy, interval debulking surgery was considered for
those patients who had not undergone optimal debulking at their
first operation. Paclitaxel was given as a 1-h infusion in 250ml 5%
glucose, followed by gemcitabine as a 30-min infusion in 250ml
0.9% saline. Standard premedications, such as dexamethasone and
5HT3 antagonists, were used.
Full doses of carboplatin were given if neutrophils were
X1.5 10
9l
 1 and platelets were X100 10
9l
 1 on the day of
treatment. If, on the day of treatment, neutrophil and platelet levels
were not within these ranges, carboplatin was delayed for up to 2
weeks. A delay of 42 weeks for haematological recovery
necessitated withdrawal from study treatment. If the blood count
had recovered between 1 and 2 weeks or if prolonged neutropenia,
neutropenic sepsis, or complicated grade 4 thrombocytopenia
occurred, the subsequent dose of carboplatin was reduced by 1
AUC level. If the toxicity persisted, the carboplatin dose could only
be reduced to AUC 5 before withdrawal of the patient from the
study.
During weekly paclitaxel/gemcitabine treatment, the same
minimum threshold for a treatment day blood count was employed
as above. However, after several patients had experienced dose
delays, it was decided to amend the threshold for an acceptable
neutrophil count. Thus, on each treatment day (days 1, 8, and 15),
full doses of all drug(s) were given if neutrophils were
X1.0 10
9l
 1 and platelets were X100 10
9l
 1. If these levels
were not reached, treatment was delayed for up to 2 weeks. A delay
of more than 2 weeks for haematological recovery necessitated
removal from study treatment. If blood counts recovered between
1 and 2 weeks or if neutropenic sepsis or complicated grade 4
thrombocytopenia occurred, the subsequent doses of both drugs
were reduced by 25%. If grade 3/4 mucositis (or at physician’s
discretion if grade 2) or Xgrade 2 skin toxicity occurred,
treatment was delayed. For subsequent cycles, paclitaxel/gemcita-
bine doses were reduced by 25%. Treatment was stopped if grade
3/4 neurotoxicity or ototoxicity occurred. If hypersensitivity
reactions to paclitaxel occurred, the infusion was stopped
immediately and treated accordingly, or restarted after recovery
at the discretion of the attending physician. If the appearance of
any intrapulmonary infiltrates and/or the development of any
unexplained pulmonary symptoms such as dyspnoea, wheezing, or
cough occurred, treatment was delayed until pathogenesis could be
determined. If this was drug-related, the patient did not receive
further therapy.
Baseline and treatment assessments
Prior to study entry, each patient underwent a standard physical
examination (including neurological and pelvic examination) with
an electrocardiogram and chest X-ray. Disease state via radi-
ological assessment per abdominal and pelvic computed tomo-
graphy (CT), ECOG performance status, weight, and GFR were also
assessed at baseline.
Safety assessments were conducted at the start of treatment and
included full blood count (FBC) including differential white cell
count and full biochemical profile (urea, creatinine, sodium,
potassium, calcium, magnesium, AST, ALT, ALP, bilirubin, total
protein, albumen, and glucose). Glomerular filtration rate was
measured using
51Cr EDTA. The FBC and biochemical profile were
performed on day 1 of carboplatin therapy and weekly during
paclitaxel and gemcitabine therapy.
Before each cycle of therapy, a standard physical exam was
performed, and toxicity, performance status, and weight were
reassessed. Chest X-rays were repeated during the carboplatin
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lcycles if disease was evident at baseline or if clinically indicated.
An additional CT scan and chest X-ray were performed before and
after the four cycles of paclitaxel and gemcitabine if evaluable
disease was evident at baseline, if progressive disease occurred, or
if the patient underwent interval debulking. A physical examina-
tion and neurotoxicity assessment were also performed, before and
after the four cycles of paclitaxel and gemcitabine. All patients
received a chest X-ray prior to each cycle of paclitaxel and
gemcitabine therapy.
Clinical response was determined by CT scan in patients with
measurable disease at the start of chemotherapy. If the CT scan
showed evaluable disease, patients were deemed evaluable for
response. Scans were performed at baseline and repeated after the
four cycles of carboplatin (both before and after surgery if interval
debulking was performed) and once all eight cycles of chemother-
apy were completed. Standard WHO clinical response criteria were
used.
CA 125 levels were measured before each cycle of chemotherapy.
For the patients with an elevated CA 125 at the start of therapy, the
proportions of patients with CA 125 reductions 475 and 50%
from baseline were determined after the four cycles of carboplatin
(and before any interval debulking) and again at the completion of
chemotherapy.
Disease progression was defined by radiological findings or by a
rising CA 125 in association with symptoms. CA 125 elevation
alone, in the absence of clinical evidence of relapse, was not
sufficient evidence for progression. Progression-free survival for
all patients was recorded from the date of the first cycle of
chemotherapy until disease progression or death from any cause,
and overall survival from the date of the first cycle of
chemotherapy until death from any cause. Kaplan–Meier progres-
sion-free and overall survival curves were generated.
Statistical considerations
This was a phase II trial conducted at two cancer centres in the
United Kingdom. The trial was designed to assess whether the
experimental regimen was feasible as determined by the propor-
tion of patients completing all the eight cycles of chemotherapy.
The number of patients required for study entry was based on the
premise that X80% is clearly an acceptable study completion rate,
60–80% is a ‘grey area,’ and p60% is clearly unacceptable. The
study was designed to test the null hypothesis that the completion
rate is p60% against the alternative that it is 460%. The one-
sided significance level was set at 5% and the power of the study
for a true completion rate of 80% was set at 90%. This necessitated
a target enrolment of 44 patients.
RESULTS
Patient characteristics
Between January 2001 and January 2002, 53 patients were enrolled
into the study. The majority of patients had advanced stage
ovarian cancer, with six patients (11%) having stage IV and 31
(58%) stage III disease (Table 1). In all, 20 patients had no residual
macroscopic disease after surgery, 11 patients had 2cm or less, and
22 patients (42%) had 42cm of residual disease prior to
chemotherapy. A total of 39 patients (74%) had an elevated CA
125 at baseline and 32 (60%) had radiologically evaluable disease.
The majority of patients (72%) had either serous/papillary or
endometroid histological subtypes of ovarian cancer.
Drug administration
A total of 38 patients (72%) completed all eight cycles of treatment.
In all, 15 patients did not complete the full course of therapy; four
due to disease progression, 10 due to toxicities, and one due to
patient choice. Patients completed a total of 203 cycles of
carboplatin and a 167 cycles of paclitaxel/gemcitabine, for a total
of 370 cycles completed. Doses were reduced in 12 carboplatin
cycles (6%) and 15 paclitaxel/gemcitabine cycles (9%). Doses were
delayed in 37 carboplatin cycles (18%) due to lack of haematologic
recovery by day 21 and in 19% of paclitaxel/gemcitabine cycles
primarily due to myelosuppression.
Toxicity
Neutropaenia was the major haematological toxicity encountered
for the 51 patients evaluable for toxicity (two patients who
developed disease progression during the second cycle of carbopla-
tin were not considered evaluable for toxicity) (Table 2). Grade 4
neutropenia occurred in 37% of patients during carboplatin therapy
and 57% of patients during paclitaxel/gemcitabine therapy. No
episodes of febrile neutropenia were reported during the conduct of
the study. Thrombocytopenia was infrequent, with 18 and 11% of
patients developing grade 3/4 thrombocytopenia with carboplatin
and paclitaxel/gemcitabine, respectively, and was not associated
with any clinical complications.
During carboplatin therapy, grade 3 nausea and vomiting was
the most common nonhaematological toxicity, occurring in 10% of
patients (Table 3). The predominant grade 3/4 nonhaematological
toxicities for paclitaxel/gemcitabine treatment were lethargy/
fatigue (8%) and infection (4%). Alopecia, nausea and vomiting,
and neuropathy occurred infrequently during the conduct of the
study.
Several patients developed respiratory symptoms and, as a
consequence, pulmonary toxicity was examined in more detail.
Table 1 Baseline characteristics of patients (n¼53)
Age (years)
Median (range) 59 (29–77)
FIGO stage
Ic 11 (21%)
II 5 (9%)
III 31 (58%)
IV 6 (11%)
CA 125 elevated 39 (74%)
Histology
Serous/papillary 27 (51%)
Endometroid 11 (21%)
Clear cell 3 (6%)
Mucinous 3 (6%)
Other 8 (15%)
Unknown 1 (2%)
Residual disease
Microscopic 20 (38%)
p2cm 11 (21%)
42cm 22 (42%)
FIGO¼International Federation of Gynaecology and Obstetrics.
Table 2 Worst grade 3/4 haematological toxicity by patient (n¼51)
Carboplatin Paclitaxel/Gemcitabine
Grade
3( % )
Grade
4( % )
Grade
3( % )
Grade
4 (%)
Anaemia (4) (2) 0 0
Thrombocytopenia (10) (8) (4) (7)
Neutropenia (20) (37) (28) (57)
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lOne patient (2%) developed pneumonia while receiving carbopla-
tin; this was thought to be unrelated to chemotherapy. In all, 10
patients had some degree of symptomatic pulmonary toxicity
during treatment with gemcitabine/paclitaxel. Two patients devel-
oped breathlessness that was thought to be unrelated to treatment
(one had an exacerbation of asthma diagnosed by a respiratory
physician and another a Haemophilus Influenza pneumonia).
Eight developed symptoms of dyspnoea (three grade 3 and five
grade 2) that were considered related to chemotherapy with or
without decreased DLCO and radiological interstitial lung changes.
Four developed symptoms in cycle five, one in cycle 6, one in cycle
7 and two in cycle 8. These events are now described.
One woman developed shortness of breath at rest in cycle 7
(CTC grade 3) associated with pulmonary infiltrates on chest X-ray
and decreased DLCO. She received corticosteroids, but subse-
quently developed disease progression with pleural effusions. Two
patients developed acute onset grade 3 dyspnoea and cough in
cycle 5, their symptoms resolved in 1 week and no further
gemcitabine was given. Five patients developed shortness of breath
on exertion only (CTC grade 2). Two of these patients developed
symptoms in cycle 5; one was given corticosteroids and in both
cases toxicity was reversible and short lived. Three further patients
developed CTC grade 2 dyspnoea. One patient who developed
symptoms in cycle 6 developed further respiratory problems
caused by multiple pulmonary emboli 3 months later. The two
other patients developed grade 2 dyspnoea in cycle 8, which
resolved in 4 weeks and 4 months, respectively.
Efficacy
After the four carboplatin cycles and before any further surgery, 10
of the 32 patients (31%) with measurable disease achieved a
complete response (CR) and 16 patients (50%) had a partial
response (PR) for a response rate of 81% (Table 4). Stable disease
(SD) was reported in four patients (16%) and two patients (6%)
progressed. Five patients (9%) underwent interval debulking
surgery, two of whom had complete resection of all macroscopic
disease. On the subsequent weekly paclitaxel/gemcitabine regimen,
three of the 16 patients with PR achieved CR, and a patient with SD
achieved PR. Thus, the overall response rate was 84% (CR 13 out of
32, PR 14 out of 32). Of the remaining 21 patients with non-
measurable or non-evaluable disease, none had progressed at the
end of therapy. Of the three patients with clear cell histology, two
had evaluable disease and both achieved CR. Of the three patients
with mucinous histology, two had nonevaluable disease and one
developed PD.
Of the 39 patients with elevated CA 125 at baseline, 82% had a
450% decrease in CA 125 and 72% had a 475% decrease after
four cycles of carboplatin. At the end of chemotherapy, these rates
were 82 and 77%, respectively (Table 4).
As of March 2004, with a median follow-up of 28 months, 31
patients had relapsed. The median progression-free survival was
19.5 months (95% CI: 13.4–25.6 months, Figure 1). Median overall
survival has not yet been reached, and 79.2% of patients were alive
at 2 years (95% CI: 65.5–87.9%).
Table 3 Worst grade nonhaematological toxicity by patient (n¼51)
Carboplatin Paclitaxel/Gemcitabine
Grade 3
a Grade 3
a
Alopecia 0 0
Nausea/vomiting (10) 0
Neuropathy (2) 0
Diarrhoea 0 (2)
Constipation 0 (2)
Stomatitis (2) 0
Infection 0 (4)
Lethargy/fatigue (2) (8)
Anxiety 0 (2)
Pulmonary (2) (2)
aNo grade 4 nonhaematological toxicity was seen.
Table 4 Response assessment
Post carboplatin Overall
WHO response (n¼32)
CR 10 (31%) 13 (40%)
PR 16 (50%) 14 (44%)
CR+PR 26 (81%) 27 (84%)
SD 4 (13%) 1 (3%)
PD 2 (6%) 4 (13%)
CA 125 response (n¼39)
475% decrease 28 (72%) 30 (77%)
450% decrease 32 (82%) 32 (82%)
o50% decrease 2 (5%) 2 (5%)
Increase 2 (5%) 2 (5%)
Unknown 3 (8%) 3 (8%)
WHO¼World Health Organisation; CR¼complete response; PR¼partial re-
sponse; SD¼stable disease; PD¼progressive disease; CA¼cancer antigen.
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Figure 1 Kaplan–Meier analysis of PFS and overall survival (OS) of all
patients. Median follow-up 28 months. Median PFS 19.5 months (95% CI:
13.4–25.6 months). PFS at years 1 and 2 and OS at year 2 are indicated
with error bars showing 95% confidence intervals.
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lDISCUSSION
The current study is part of a portfolio of studies conducted by the
Scottish Gynaecological Cancer Trials Group (SGCTG) to examine
the feasibility of sequential chemotherapy scheduling. The
schedule chosen for this study mirrored the weekly arm of the
SGCTG Scottish Randomised Trial in Ovarian Cancer (SCOTROC)
2a trial, in which patients received four cycles of carboplatin AUC
7 every 3 weeks, followed by four cycles of docetaxel 25mgm
 2
and gemcitabine 800mgm
 2, both drugs given on days 1, 8, and 15
every 3 weeks (Vasey et al, 2003). Although the SGCTG has
recently demonstrated that docetaxel has equivalent efficacy to
paclitaxel in first-line therapy (Vasey, 2001, 2002), we used the
more established taxane in ovarian cancer, paclitaxel.
Our study demonstrated that sequential treatment with four
cycles of carboplatin AUC 7 followed by paclitaxel and gemcitabine
is feasible as primary treatment for advanced ovarian cancer with
72% of patients being able to complete all the eight cycles of
treatment. This is an active regimen with an overall radiological
response rate of 84% and 475% decrease in CA 125 seen in 72% of
patients. In all, 37 out of 53 (70%) patients had initial stage III or
IV disease, of whom 15 (40%) had been optimally debulked at
primary surgery. These figures are at least comparable with the
response and progression-free survival data seen in large
international randomised trials of platinum–taxane combinations.
The median progression-free survival was 19.5 months (95% CI:
13.4–25.6 months), which, despite the median duration of follow-
up being 28 months, should be fairly accurate as more than half the
total patients have progressed. In the SCOTROC II trial in which
500 patients received conventional paclitaxel/carboplatin therapy,
the median progression-free survival was 15 months (Vasey, 2001,
2002). Thus, the progression-free survival reported here is
encouraging, given both trials enrolled similar patient populations.
Gemcitabine, platinum, and paclitaxel as a triplet combination
for first-line therapy of ovarian cancer has been developed by
Hansen and colleagues (Hansen et al, 1999; Hansen, 2002). Patients
with recurrent, pretreated disease were given cisplatin 75mgm
 2
(on day 1), paclitaxel 175mgm
 2 (on day 1), and gemcitabine
1000mgm
 2 (on days 1 and 8), whereas untreated patients (and
relapsed patients demonstrating severe toxicity with the former
regimen) were given carboplatin AUC 5 (on day 1), paclitaxel
175mgm
 2 (on day 1) and gemcitabine 800mgm
 2 (on days 1
and 8). The extremely promising overall response rate of 100% in
25 evaluable patients (radiological and/or CA 125) occurred at the
expense of considerable haematologic toxicity.
In our trial, the incidence of infection, sensory neuropathy, and
alopecia was low; however, the rate of pulmonary toxicity with
weekly gemcitabine/paclitaxel therapy was of concern with a
pattern of breathlessness, interstitial lung changes, and decreased
DLCO in several patients. The symptoms were generally mild and
reversible. As this pattern was recognised during the course of the
study, it is not possible to determine if there were any predisposing
factors such as smoking, or pre-existing respiratory disease.
Trials in non-small-cell lung cancer of weekly taxane/gemcita-
bine combinations have also identified this toxicity although it is
very difficult to accurately identify pulmonary toxicity in this
patient group. Bhatia et al conducted a phase II trial of weekly
gemcitabine and paclitaxel in previously untreated patients.
Gemcitabine 1000mgm
 2 and paclitaxel 110mgm
 2 were given
on days 1, 8, and 15 every 28 days. Four patients (10%) developed
hypoxia with interstitial lung shadowing on chest X-ray, and one
patient died (Bhatia et al, 2002). Thomas et al also reported
pneumonitis as the dose-limiting toxicity in a phase I/II trial of
weekly gemcitabine and paclitaxel, and the trial was stopped after
enrolling 12 patients as four patients experienced this toxicity
(Thomas et al, 2000). In the SGCTG trial that was running
concurrently in the United Kingdom, a similar phenomenon was
seen in the patients who received the weekly docetaxel/gemcitabine
(Vasey et al, 2003). Thus, it would appear that this toxicity might be
particularly prevalent in the taxane/gemcitabine weekly schedules.
In summary, the approach of using sequential carboplatin
followed by paclitaxel/gemcitabine is feasible, and the efficacy data
are encouraging; however, the incidence of pulmonary toxicity is
of some concern and may limit the use of this weekly regimen.
Thus, the SGCTG are currently proposing to evaluate sequential
carboplatin followed by the combination of gemcitabine/paclitaxel,
but with a more conventional 3-week taxane dosing.
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